Conor Barry, PhD, Vice President and Global Head of R&D for Bioconjugates and Large Molecules at Piramal Pharma Solutions, discusses the evolving antibody-drug conjugate (ADC) landscape and how the company’s strategic investments and ADCelerate program are simplifying complex supply chains for global partners.
The ADC landscape is evolving toward a broader range of bioconjugate modalities, driven in part by increasing demand for larger production batch sizes. As pharmaceutical companies manage more complex supply chains, from protein production through sterile fill-finish, Piramal Pharma Solutions is positioning itself as a strategic partner capable of supporting the full development lifecycle.
In this interview, Conor Barry, PhD, explains how the company leverages its global network of 15 manufacturing facilities to deliver flexible, end-to-end support across both clinical and commercial manufacturing. To meet growing industry demand, the organization has made significant capital investments across its network, ensuring that capacity is in place as client programs scale and advance toward larger patient populations. Barry also highlights ADCelerate, a specialized program designed to accelerate early-stage clinical manufacturing and streamline the path to first-in-human studies.
Sponsored
Sponsored
